GoodinDSHartungHPO’ConnorPFilippiMArnasonBComiG. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler J2011 (in press).
2.
DuquettePGirardMDuboisRKoblerRLLublinFKelleyL. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology1996; 47: 889–894.
GoodinDSFrohmanEMHurwitzBO’ConnorPWOgerJJRederAT. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2007; 68: 977–984.
5.
SørensenPSDeisenhammerFDudaPHohlfeldRMyhrKMPalaceJ. Guidelines on use of anti-interferon-beta antibody measurements in multiple sclerosis - Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol2005; 12: 817–827.
6.
PolmanCHBertolottoADeisenhammerFGiovannoniGHartungHPHemmerB. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol2010; 9: 740–750.
7.
SominandaAHillertJFogdell-HahnA. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry2008; 79: 57–62.
8.
SørensenPSTscherningTMathiesenHKLangkildeARRossCRavnborgM. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology2006; 67: 1681–1683.
9.
SørensenPSKoch-HenriksenNBendtzenK. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?Mult Scler2007; 13: 616–621.
10.
SørensenPSKoch-HenriksenNRossCClemmesenKMBendtzenK. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology2005; 65: 33–39.
